期刊文献+

诱导型环氧合酶在人冠状动脉粥样硬化组织中的表达分布 被引量:7

Distribution of Induced Cyclooxygenase Expression in Atherosclerotic Coronary Artery
下载PDF
导出
摘要 为探讨诱导型环氧合酶在人冠状动脉不同动脉粥样硬化病变类型间的分布。收集 15例尸检的人冠状动脉共 4 5个标本 ,根据HE染色病理特征及AHA标准分为 3组 ,其中正常冠状动脉对照 3个 ;纤维斑块或Ⅴ型病变(稳定斑块 )标本 2 2个 ;粥样硬化斑块伴有不同程度炎症反应的复合斑块或Ⅵ型病变 (不稳定斑块 )冠状动脉标本2 0个。分别采用免疫组织化学染色和逆转录聚合酶链反应方法 ,检测诱导型环氧合酶蛋白和mRNA在以上不同类型标本中的分布表达。结果发现 ,诱导型环氧合酶主要表达分布于动脉粥样硬化组织斑块区 ,在复合斑块中诱导型环氧合酶的表达明显高于纤维斑块 (诱导型环氧合酶灰度值 14 7.0± 1.1比 5 6 .2± 4 .4 ,P <0 .0 1) ,而在非斑块区和正常冠状动脉中均未检测到诱导型环氧合酶的表达。结果提示 ,诱导型环氧合酶参与了动脉粥样硬化病理发生以及斑块稳定性中炎性反应的调控过程 ,抑制斑块局部诱导型环氧合酶的高表达 。 Aim To evaluate the distribution of induced cyclooxygenase (COX-2)expression in human coronary arteries with different atherosclerotic lesions. Methods 45 coronary arteries specimens from 15 autopsy cases were divided into 3 groups according to pathologic features of HE staining and AHA definition respectively,which were 3 healthy coronary arteries as control,22 fibrotic plaque or type Ⅴ lesion specimens (representing stable plaque),and 20 complicated plaque or type Ⅵ lesion specimens (representing unstable plaque). RT-PCR were performed for mRNA analysis,and immunohistochemical staining were used for location of protein. Results COX-2 was found in the areas of plaques but not in healthy or nonatherosclerotic vascular walls. COX-2 expression in complicated plaques was significantly higher than in fibrous plaques (COX-2 expression 147.0±1.1 vs 56.2±4.4,P<0.01). Conclusions These findings suggests that COX-2 might play a role in pathogenesis of atherosclerosis,and modulation of inflammatory process involved in plaque stability. Inhibition of COX-2 over-expression in plaque areas might be a potential approach to atherosclerosis treatment and plaque stabilization.
出处 《中国动脉硬化杂志》 CAS CSCD 2004年第5期533-536,共4页 Chinese Journal of Arteriosclerosis
关键词 诱导型 环氧合酶 冠状动脉 表达 斑块 动脉粥样硬化 标本 标准分 不同类型 中正 Atherosclerosis Plaque Cyclooxygenase-2 COX-2
  • 相关文献

参考文献15

  • 1Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340 (2): 115-126
  • 2Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol, 2002, 507: 177-184
  • 3Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyccloxygenase-2 in human atherosclerotic lesions. Am J Pathol, 1999, 155 (4): 1 281-291
  • 4Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol, 1999, 19 (3): 646-655
  • 5Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 2002, 105 (15): 1 816-823
  • 6翁少翔,单江,徐耕,马骥.小白菊内酯抑制胎牛血清诱导的大鼠血管平滑肌细胞增殖及信号转导机理[J].中国药理学与毒理学杂志,2002,16(5):331-335. 被引量:10
  • 7Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation, 1995, 92 (5): 1 355-374
  • 8Mitchell JA, Warner TD. Cyclo-oxygenase-2:pharmacology,physiology,biochemistry and relevance to NSAID therapy. Br J Pharmacol, 1999, 128 (6): 1 121-132
  • 9Massy ZA, Swan SK. Cyclooxygenase-2 and atherosclerosis:friend or foe? Neph Dial Tran, 2001, 16 (12): 2 286-289
  • 10Shiokoshi T, Ohsaki Y, Kawabe J, Fujino T, Kikuchi K. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells. J Hypertens, 2002, 20 (3): 455-461

二级参考文献17

  • 1Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E. Ethnopharmacology of Mexican Asteraceae (Compositae)[J]. Annu Rev Pharmacol Toxicol, 1998, 38(6):539-565.
  • 2Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion[J]. Planta Med, 1999, 65(2):126-129.
  • 3Zingarelli B, Hake PW, Denenberg A, Wong HR. Ses- quiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury[J]. Shock, 2002, 17(2):127-134.
  • 4Wong HR, Menendez IY. Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells[J]. Biochem Biophys Res Commun, 1999, 262(2):375-380.
  • 5Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease[J]. Circ Res, 1998, 82(3):396-403.
  • 6Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells[J]. J Biol Chem, 2000, 275(29):22435-22441.
  • 7Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases[J]. Biochem Biophys Res Commun, 1996, 226(3):810-818.
  • 8Fukuda K, Hibiya Y, Mutoh M, Ohno Y, Yamashita K, Akao S, et al. Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1[J]. Biochem Pharmacol, 2000, 60(4):595-600.
  • 9Hehner SP, Hofmann TG, Droge W, Schmitz ML. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex[J]. J Immunol, 1999, 163(10):5617-5623.
  • 10Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B[J]. Annu Rev Cell Biol, 1994, 10(4):405-455.

共引文献9

同被引文献71

  • 1李敏侠,刘必成.血管紧张素Ⅱ和微炎症反应[J].国际泌尿系统杂志,2006,26(1):139-143. 被引量:3
  • 2[1]Paramo JA,Rodriguez JA,Beloqui O,Orbe J.Monocyte cyclooxygenase-2 activity:a new therapeutic target for atherosclerosis[J]? Curr Drug Targ Cardiovasc Haematol Disord,2005,5 (4):303-311.
  • 3[2]Burleigh ME,Babaev VR,Yancey PG,Major AS,McCaleb JL,Oates JA,et al.Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice[J].Mol Cell Cardiol,2005,39 (3):443-452.
  • 4[4]Ohnaka K,Numaguchi K,Yamakawa T,Inagami T.Induction of cyclooxygenase-2 by angiotensin Ⅱ in cultured rat vascular smooth muscle cells[J].Hypertension,2000,35 (1 Pt1):68-75.
  • 5[5]Francesco Cipollone,Bianca Rocca,Carlo Patrono.Cyclooxygenase-2 expression and inhibition in atherothrombosis[J].Arterioscler Thromb Vasc Biol,2004,24 (2):246-255.
  • 6[6]Cipollone F,Fazia M,Mezzetti A.Novel determinants of plaque instability[J].Thromb Haemost,2005,3 (9):1 962-975.
  • 7[7]Cipollone F,Fazia M,Iezzi A,Zucchelli M,Pini B,De Cesare D,et al.Suppression of the functionally coupled cyclooxygenase-2/PGE synthase as a basis of simvastatin-dependent plaque stabilization in humans[J].Circulation,2003,107 (11):1 479-485.
  • 8[8]Mezzetti A.Pharmacological modulation of plaque instability[J].Lupus,2005,14 (9):769-772.
  • 9[11]Veillard NR,Mach F.Statins:the new aspirin[J]? Cell Mol Life Sci,2002,59 (11):1771-786.
  • 10[12]Min-Jean Yin,Yumi Yamamoto,Gaynor RB.The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta[J].Nature,1998,396 (6706):77-80.

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部